NASDAQ · APEN
Apollo Endosurgery, Inc.
$10.00$0.00 (0.0%)
Apollo Endosurgery, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.91% below the high.
Loading market information…
NASDAQ · ZIMV · USD
Stock price, earnings
Quote as of Oct 20, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
ZimVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.11% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow ZimVie Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ZimVie Inc. operates as a medical technology enterprise, specializing in the design, manufacturing, and global distribution of an extensive array of products and solutions. These offerings are engineered to address various spinal conditions and facilitate dental tooth replacement and restorative procedures. Its comprehensive dental portfolio encompasses implant systems, along with associated prosthetic and abutment components, and the necessary surgical instrumentation and kits. The company also supplies advanced regenerative products such as bone grafts, barrier membranes, allografts, and collagen-based wound care solutions. Furthermore, it provides cutting-edge digital dentistry tools, including intraoral scanners, virtual treatment planning services, guided surgery capabilities, CAD/CAM workflow systems, and customized restorative parts. In the spinal segment, ZimVie offers a range of fusion implants and specialized instrumentation for diverse surgical interventions, including biologics and innovative bone healing technologies. Notably, its specialized spinal offerings include minimally invasive surgery (MIS) solutions, exemplified by products like Vital MIS and Timberline, as well as advanced motion preservation technologies such as Mobi-C and The Tether. Established in 2021, ZimVie Inc. maintains its corporate headquarters in Westminster, Colorado.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:08 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2024 | May 8, 2024 | $0.08+300.0% vs estimate | $118.20M+1.72% vs estimate |
|---|
| Q4 2023 | Feb 28, 2024 | $0.10-23.08% vs estimate | $113.07M-47.03% vs estimate |
|---|
THE ANALYST VIEW
6 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.00$0.00 (0.0%)
Apollo Endosurgery, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.91% below the high.
$18.63+$1.41 (+8.19%)
GRAIL, Inc. Common Stock’s quoted price sits in the upper half of its reported 52-week range, 20.25% below the high.
$5.59-$0.01 (-0.09%)
BioDelivery Sciences International, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.53% below the high.
$7.02$0.00 (0.0%)
Accolade, Inc.’s quoted price sits in the upper half of its reported 52-week range, 27.4% below the high.
$8.16$0.00 (0.0%)
Regulus Therapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.22% below the high.
$8.68$0.00 (0.0%)
Sage Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 7.26% below the high.
$1.43-$0.01 (-0.35%)
Sharecare, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.69% below the high.
$6.47$0.00 (0.0%)
Sinovac Biotech Ltd.: Healthcare · Medical - Pharmaceuticals.
